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Anticancer eﬀects of lactoferrin: underlying mechanisms and
future trends in cancer therapy
Yunlei Zhang, Cristovao F Lima, and Ligia R Rodrigues
Lactoferrin has been widely studied over the last 70 years, and its role in diverse
biological functions is now well known and generally accepted by the scientiﬁc
community. Usually, alterations of the lactoferrin gene in cells are associatedwith an
increased incidence of cancer. Several studies suggest that exogenous treatment
with lactoferrin and its derivatives can eﬃciently inhibit the growth of tumors and
reduce susceptibility to cancer. None of these studies, however, reported a consistent
outcome with regard to the mechanisms underlying the anticancer eﬀects of
lactoferrin. In this review, the association of lactoferrin with cancer is thoroughly
discussed, from lactoferrin gene expression to the potential use of lactoferrin in
cancer therapy. Lactoferrin cytotoxicity against several cancers is reported to occur in
distinct ways under diﬀerent conditions, namely by cell membrane disruption,
apoptosis induction, cell cycle arrest, and cell immunoreaction. Based on these
mechanisms, new strategies to improve the anticancer eﬀects of the lactoferrin
protein and/or its derivatives are proposed. The potential for lactoferrin in the ﬁeld of
cancer research (including as a chemotherapeutic agent in cancer therapy) is also
discussed.
© 2014 International Life Sciences Institute
INTRODUCTION
Lactoferrin, an 80-kDa protein with iron-binding ability,
was ﬁrst discovered in mammary secretions but is syn-
thesized by most mammalian tissues.1 It is present in high
concentrations in human (1.0 to ≈3.2 mg/mL) and bovine
milk (0.02 to ≈0.35 mg/mL) and in lower concentrations
in a variety of secretions derived from epithelial cells as
well as in the second granules of neutrophils.2,3 This wide
distribution indicates that lactoferrin is possibly involved
in multiple important physiological activities.
Many relevant biological functions have been
reported for lactoferrin, including anticancer, antibacte-
rial, antiviral, antifungal, anti-inﬂammatory, and immune
regulatory activities.4,5 Some studies indicate that the
iron-binding ability of lactoferrin and the interaction
between lactoferrin and its speciﬁc receptors are respon-
sible for the diverse biological functions demonstrated
thus far.4 In addition, lactoferrin-derived peptides and the
iron-saturated form of lactoferrin (hololactoferrin) have
also been shown to be eﬃcient anticancer and antibacte-
rial drugs.2 The most-studied lactoferrin-derived peptide
is bovine lactoferricin B, a cationic antimicrobial peptide
derived from the N-terminal of the protein lactoferrin.6
This peptide, like the protein, has been the object of
increasing interest. However, the detailed mechanisms
underlying the broad range of functions of lactoferrin
and its derivatives still need to be clariﬁed. Insight into the
role of lactoferrin in cancer development and progression
has been provided through published data on the anti-
cancer mechanisms of lactoferrin. For example, studies
have shown that the downregulation or silencing of
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lactoferrin or cytosolic lactoferrin (delta lactoferrin)
genes in cells leads to an increase of malignant tumors.7,8
In contrast, the proliferation of cancer cells is blocked
following restoration of the lactoferrin gene.9,10 Addition-
ally, several reports have shown that lactoferrin and/or its
derivatives can inhibit the growth of tumors both in vitro
and in vivo.11–19
Besides having nutritional value, lactoferrin and/or
its derivatives may have considerable potential in the pre-
vention and treatment of cancer. The present review aims
to provide an outline of their mechanisms of action
against cancer as well as their possible applications in the
ﬁeld of cancer research.
LACTOFERRIN GENE EXPRESSION AND DECREASED
CANCER SUSCEPTIBILITY
Lactoferrin protein is widely distributed in mammalian
cells. The synthesis of lactoferrin mRNA is regulated
either directly or indirectly by estrogen, retinoic acid,
mitogen, and growth factors. The multiple response ele-
ments lie mainly in the 3 short, but complex, modules
within 400 bp of the transcription site of the lactoferrin
gene.20 For example, the human lactoferrin gene pro-
moter (P1) contains 2 chicken ovalbumin upstream
promoter transcription factor elements, one of which
is overlapped with the estrogen response element,
while the other is present within a composite response
element adjacent to the estrogen response element.21
Overexpression of the chicken ovalbumin upstream
promoter transcription factor can block the estrogen-
stimulated responses.22 The infection-responsive pro-
moter in lactoferrin gene has also been characterized.
Lipopolysaccharide-responsive regions of the promoter
contain 1 signal transducer and activator of transcrip-
tions (STAT3) site, 3 activator protein 1 sites, and 8
nuclear factor-κB sites. Lactoferrin promoter may
respond to infections via the nuclear factor-κB pathway.23
This observation explains the large increase in lactoferrin
concentrations in mammary secretions infected by bac-
teria. The expression of the lactoferrin gene is stimulated
mainly by bacterial lipopolysaccharide and double-strand
RNA.24 In addition, expression of lactoferrin inmammary
epithelial cells is mediated by changes in cell shape and
the actin cytoskeleton.25 Furthermore, miR-214,
expressed in 23 species, was found to be directly involved
in lactoferrin expression and the lactoferrin-mediated
cancer susceptibility in mammary epithelial cells.26
Some of these response elements in the lactoferrin
gene, such as the estrogen and infection response ele-
ments, may be implicated in an increased cancer inci-
dence. Estrogen can promote DNA synthesis and cell
proliferation by turning on estrogen-responsive genes.
Exposure to an excess of estrogen will greatly increase the
incidence of breast cancer.27,28 On the other hand, it is well
known that 1 out of 6 cancers develops from infection,29
and suppression of infection plays an important role in
cancer therapy after chemotherapy or bone marrow
transplantation.30 The regulatory elements responding to
pathogenic factors are involved in expression of the
lactoferrin gene. This indicates that lactoferrin probably
acts as a negative regulator in the human body to repress
the acute reaction to estrogen or to kill virus and bacterial
infection by sharply raising the protein expression.Addi-
tionally, potent antimicrobial and antiviral eﬀects have
been associated with the use of exogenous lactoferrin.1,2
These properties can be very helpful in the prevention of
infections and cancer recurrence after chemotherapy
treatments. Complete knowledge about these lactoferrin
gene regulatory factors constitutes a useful basis for
designing novel strategies for possible uses that may
include the exogenous supply of the protein lactoferrin.
LACTOFERRIN GENE EXPRESSION AND GENETIC
VARIATION IN CANCER CELLS
A relationship between lactoferrin gene expression and
susceptibility to breast cancer was ﬁrst proposed by
Furmansiki et al.,31 who found that lactoferrin-associated
RNase activity was present at lower levels in milk
obtained from a consanguineous community with a high
incidence of breast cancer in India. Recent studies also
showed that both the P1 and P2 promoter regions of the
lactoferrin gene are downregulated or silenced in several
cancer cell lines.7 This downregulation is much more
apparent for delta lactoferrin, the expression of which is
either signiﬁcantly diminished (in BT-20 and MCF-7
cells) or practically absent (in MDA-MB-231, T-47D, and
HBL 100 cells) in cancerous tissue,8 though it is regularly
expressed in normal tissues. Moreover, stable expression
of delta lactoferrin or overexpression of lactoferrin led to
signiﬁcant inhibition of cancer cell growth as well as to a
weakened potential to form in vivo tumors after
orthotopic transplantation.9,10
Besides revealing the distinct levels of lactoferrin
expression in normal as well as in cancerous tissues, the
evaluation of the lactoferrin gene structure showed that
the degree and pattern of methylation are notably altered
in malignant breast cells.32,33 For instance, a lactoferrin
cDNA clone extracted from human breast tissue was used
to evaluate changes in the restriction fragment length and
the methylation patterns of DNA from normal peripheral
blood, from leukemia cells from patients, and from leu-
kemia and breast cancer cell lines. Patterns of DNA
methylation in malignant cells were found to be highly
variable. However, DNA was generally less methylated
than in normal cells.33 In addition, methylation assays
conducted in a model of nasopharyngeal cancer demon-
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strated that methylation also occurred in the promoter of
the lactoferrin gene, which is linked to decreased
lactoferrin gene expression. Simultaneously, abnormal
migration patterns of the lactoferrin gene were also found
in cancer cells.More speciﬁcally, the alternation generally
takes place in the lactoferrin exons 4, 5, 13, 14, and 15.34
Genetic variation of the lactoferrin gene signiﬁ-
cantly increases cancer susceptibility. The changes in
methylation of the promoter or ﬁrst exon may have the
same eﬀect as mutations of various tumor suppressor
genes or proto-oncogenes. Carcinogenesis can result
from aberrations in genomic DNA methylation, includ-
ing hypermethylation and hypomethylation of the pro-
moter or ﬁrst exon of cancer-related genes.35 Recent
studies showed that, apparently, cancer cells have a rela-
tively high occurrence of genetic polymorphisms, gene
mutations, and promoter hypermethylation in the
lactoferrin gene.32–34 All these observations suggest a
close relationship between alterations of the lactoferrin
gene and an increasing incidence of carcinomas. Hence,
the use of lactoferrin as a novel cancer-speciﬁc marker
may have applications in diagnosing cancer as well as in
gauging the prognosis of cancer patients at diﬀerent
stages.Alternatively, lactoferrin may have uses as a thera-
peutic agent in chemoprevention or in clinical practice.
Since the restoration of lactoferrin expression success-
fully depresses the growth of tumors, the lactoferrin gene
could be further explored as a new target site for cancer
gene therapy.
CHEMOPREVENTIVE POTENTIAL OF
ORAL LACTOFERRIN
The World Health Organization reported that, in 2012,
14.1 million people were newly diagnosed with cancer,
8.2 million cancer patients died, and 32.6 million people
were living with cancer (within a 5-year diagnosis) world-
wide.36 This means the incidence of cancer is still very
high and that, currently, there is no eﬀective cure, espe-
cially in patients at advanced stages of the disease. There-
fore, preventing the development of carcinomas is crucial
for decreasing the currently high mortality of cancer.
Some epidemiological studies have shown that more than
two-thirds of cancers could be prevented through the
adoption of an appropriate lifestyle.37 A diet rich in pre-
ventive agents is one of the strategies proposed to
decrease the incidence of cancer and other diseases.38
Milk-derived lactoferrin is considered a functional
protein and reaches a level of 7 g/L in colostrum.3 The
multifunctional lactoferrin could, thus, play a role in
cancer prevention.
Indeed, a large number of reports provide clear evi-
dence that oral administration of bovine lactoferrin can
eﬀectively decrease the development of chemically
induced cancers in animal models.39–42 Bovine lactoferrin
is a relatively stable protein that can be active even after
passing through the gastrointestinal tract as partially
degraded fragments (derivative peptides).43 These frag-
ments, with a molecular mass over 20 kDa, contain the
receptor-binding regions of the protein as well as the
anticancer active regions.43 An example of these frag-
ments is the lactoferricin B peptide.17,18 Moreover, these
fragments can be internalized by speciﬁc lactoferrin
receptors in the intestinal brush border membrane.44
The oral administration of 0.2% or 2% bovine lacto-
ferrin was found to decrease by 32.5% and 42.5%,
respectively, the occurrence of colon carcinogenesis in
azoxymethane-treated F344 rats.39 In a study conducted
with the 7, 12-dimethylbenz(a)anthracene-induced
hamster buccal pouch model, the incidence of
carcinogenesis was reduced by a diet containing 0.2%
bovine lactoferrin.41 Moreover, oral administration of
bovine lactoferrin showed chemopreventive activity
against tongue,39 esophagus, and lung carcinogenesis in
rats.42 The suggested chemopreventive eﬀects could be
due to the multiple functions of lactoferrin, which
include stimulation of the immune response39,40 modu-
lation of the carcinogen-metabolizing enzymes and the
oxidant-antioxidant proﬁle in the target organs,41 and
inhibition of angiogenesis.40 Regulation of the immune
function by lactoferrin may be a key factor in the mecha-
nisms of action involved in cancer prevention. Presently,
the extraction of bovine lactoferrin from milk and whey
is an industrial reality. Therefore, it is plausible that, in
the future, lactoferrin-containing supplements or the
consumption of lactoferrin-enriched dietary products
might be recommended to prevent or delay the onset of
cancer.
ANTICANCER ACTIVITY AND MECHANISMS OF ACTION
Although the exact mechanisms involved in the antican-
cer activity of lactoferrin are still unclear, they can be
generally grouped into extracellular eﬀects, intracellular
eﬀects, and immunostimulation. The extracellular eﬀects
are related mainly to the interaction of lactoferrin with
the cell membrane and membrane receptors,45,46 while
the intracellular eﬀects suggested by most studies are
related mostly to cell apoptosis and cell cycle arrest
(Table 1).9,11–15,17,19,47–52 The immunostimulatory action of
lactoferrin is achieved primarily by activating immune
cells to release tumor cytotoxic eﬀectors.49,53–56 The pro-
posed mechanisms underlying the cytotoxicity of
lactoferrin or its derivatives against cancer cells are
diverse and are derived from in vitro experiments
(Figure 1). Moreover, ﬁndings from in vivo experiments
are generally similar.39–42,49
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Toxic eﬀects of lactoferrin and its derived peptides on
the cell membrane
Lactoferrin and its derived peptides were found to be
easily internalized by cells.57,58 In Jurkat human
lymphoblastic T-cells, lactoferrin enters cells via receptor-
mediated endocytosis and is almost completely degraded
in the lysosomal compartment.58 The lactoferrin-active
peptide lactoferricin B also exhibits conformation-
dependent uptake eﬃciency.59 Increased membrane per-
meability may produce subtle changes in the membrane’s
barrier function that promotes cell death.At low concen-
trations, lactoferrin can increase cytolysis, while at high
concentrations it modulates cytolysis, depending on the
target cell phenotype.60 Many studies demonstrated the
presence of lactoferrin receptors on the tumor cell
surface. Heparan sulfate plays an important role in the
regulation of the binding of lactoferrin and lactoferricin B
with the receptors.57–59,61 Indeed, when it is removed, a
reduction in membrane binding and cellular uptake of
lactoferrin and lactoferricin B occurs.59,61 However, the
characterization of these receptors is still under investi-
gation, since diﬀerent cell types appear to express their
own speciﬁc lactoferrin receptors.46
Lactoferricin B is proposed to exert a higher poten-
tial activity against tumor cells than lactoferrin because it
is a cationic antimicrobial peptide.45 Some cationic anti-
microbial peptides have shown a selective activity against
cancer cells, thus constituting a promising group of novel
anticancer agents with a new mode of action and a broad
spectrum of anticancer activity.45,59 Bovine lactoferricin B
is composed of 25 amino acid residues (the residues
17–41 of bovine lactoferrin) that contain a disulﬁde
bridge between two Cys residues in positions 19 and
36.6,62 This disulﬁde bond may not be essential for main-
taining the antibacterial activity of bovine lactoferricin B,
but it is crucial for maintaining the activity against tumor
cells.62,63 In aqueous solution, bovine lactoferricin B loses
the α-helical portion of the parent protein, adopting a
slightly twisted antiparallel β-sheet amphipathic struc-
ture, with nearly all of the hydrophobic residues lining up
on one face of the peptide.6 This change causes it to bear
similarities with several major classes of cationic antimi-
crobial peptides, which contain disulﬁde bridges and
antiparallel β-strands and form amphipathic helices upon
binding to membranes.Moreover, lactoferricin B exists as
a α-helix structure when it is still linked to the parent
lactoferrin, and this is also an important feature of mem-
brane lytic peptides.64 When cationic antimicrobial
peptides come into contact with the cell membrane, they
undergo conformational changes that enable their asso-
ciation with the membrane; consequently, the cell lyses.64
Figure 1 Multiple signaling pathways potentially underlying the cytotoxic eﬀects of lactoferrin and its derivatives
against cancer cells. This ﬁgure provides further explanation of the mechanisms of action of lactoferrin and its derived
peptides against cancer cells shown in Table 1. Bovine lactoferrin and human lactoferrin exert cytotoxic eﬀects against cells by
inducing cell cycle arrest and apoptosis, while bovine lactoferricin B inhibits cell growth by triggering mitochondrial-related
apoptosis and disrupting the cell membrane. All three inhibit the activity of Akt (the down arrow) but activate p21, p27, p38,
and JNK (the up arrow) and induce the release of caspase-8, caspase-3, and cytochrome c.
Abbreviations: BLfcin B, bovine lactoferricin B; CytoC, cytochrome C; JNK, c-Jun N-terminal kinase; Akt, protein kinase B; APAF1,
apoptotic protease activating factor 1.
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It is important to notice that this mechanism is still not
entirely understood. Moreover, some cationic antimicro-
bial peptides can trigger apoptosis by disrupting the
mitochondrial membranes.65 Fluorescence-labeled
lactoferricin B has been found in the mitochondrial
membrane of neuroblastoma cells.47 Additionally, many
studies suggest that the membrane may constitute one of
the targets through which lactoferrin and lactoferricin B
exert their anticancer eﬀects.11,47
In addition to their ability to disrupt the cell mem-
brane, cationic antimicrobial peptides could also contrib-
ute to the selective toxicity of lactoferricin (peptide
derived from lactoferrin) against cancer cells. Several
studies have demonstrated that lactoferricin B or its
derivatives selectively kill cancer cells without adversely
aﬀecting normal cells.17,18,47 This could be due to the
subtle diﬀerences that exist between the cell membranes
of normal cells and those of cancer cells. The most pro-
nounced diﬀerence is a much more negatively charged
cell membrane in cancer cells.66,67 Indeed, the relatively
high levels of negatively charged molecules are likely to
be more attractive to the cationic antimicrobial peptides,
such as lactoferricin B or its variants. Therefore, these
peptides are more prone to bind to cancer cell mem-
branes, leading to cell death, than to normal cells.
Cell apoptosis
Cell apoptosis induced by lactoferrin and lactoferricin B
has been described as the pivotal pathway by which these
peptides exert their cytotoxic eﬀects against various
cancer cells. However, the apoptosis pathway that they
trigger, the extrinsic (Fas receptor family) or the intrinsic
(mitochondria-associated) pathway, apparently varies,
depending on the cell type used.9,11,17,47,50–52,68
Akt acts as an antiapoptotic signaling molecule and
plays a critical role in the function of cancer cells.69 For
example, when stomach cancer cells SGC-7901 were
treated with lactoferrin, the phosphorylated Akt and
several key proteins involved in the signaling pathway
were decreased, but expression of phosphorylated glyco-
gen synthase kinase-3β Ser256 and phosphorylated
caspase-9 Ser196 were increased, which suggests that the
lactoferrin-induced apoptosis of stomach cancer cells
SGC-7901 may be regulated via the Akt pathway.50 Fur-
thermore, lactoferrin was also found to induce a stress-
related mitogen-activated protein kinase pathway in
Jurkat T cells, where the c-Jun N-terminal kinase (JNK)
associated with Bcl-2 was presumed to be the pathway
responsible for the lactoferrin-induced apoptosis.52
Lactoferrin treatment induced the activation of caspase-9
and caspase-3 and increased the level of Bcl-2
phosphorylation. When JNK activation was abolished,
lactoferrin-treated Jurkat cells did not undergo cell
death.52 Additionally, lactoferrin induced apoptosis in the
colonmucosa of azoxymethane-treated rats by enhancing
Fas expression.68 After oral administration of lactoferrin,
Fas protein expression was augmented more than 2.5-
fold, and the active forms of both caspase-8 and caspase-3
were also higher. Immunohistochemical analysis revealed
the presence of Fas-positive and apoptotic cells preferen-
tially at the site of lactoferrin-mediated tumor inhibi-
tion.68 In addition, lactoferrin was found to protect PC12
cells from FasL-induced apoptosis at a low concentration
(50 μg/mL), while it triggered apoptosis through inhibi-
tion of the expression of phosphorylated extracellular-
signal-regulated kinase 1/2 at a high concentration
(700 μg/mL).51
Most studies with lactoferricin B demonstrate that
cells undergo the mitochondrial-related apoptosis
pathway.11,17,47 The cationic antimicrobial peptide struc-
ture of lactoferricin B may facilitate its interaction with
both surface death receptors and intracellular apoptosis-
related proteins. An example includes the apoptosis
induction in oral squamous carcinoma cells by JNK/
SAPK activation using lactoferricin B. In the process, the
JNK pathway directly activates the mitochondrial death
machinery.70
Cell cycle arrest
Besides apoptosis, cell cycle arrest is another crucial
pathway involved in the cytotoxic eﬀects of lactoferrin
against cancer cells. Lactoferrin could induce cell growth
arrest by decreasing phospho-Akt to increase the expres-
sion and activity of p21Cip1 and p27Kip1. 14,16 After exposure
to lactoferrin, the MDA-MB-231 cells stopped at the G1
to S transition phase of the cell cycle, which was associ-
ated with a dramatic decrease in the levels of proteins
Cdk2, cyclin E, and Cdk4, accompanied by an augmented
expression of the Cdk inhibitor p21Cip1.14 Cell cycle
arrest induced by lactoferrin was also demonstrated
using nasopharyngeal carcinoma cells. The expression
of cyclin D1 and phosphorylation of retinoblastoma
protein was downregulated, while expression of p21
and p27 was enhanced.9 Similar cell cycle arrest proﬁles
were found in murine squamous cell carcinoma SCCVII,
human cancer cell line O12, and canine mammary
gland adenocarcinoma cell line after treatment with
lactoferrin.48,49
Immunostimulation and iron regulation
Immunostimulation is assumed to be a key factor for
the in vivo anticancer eﬀects of lactoferrin. Both innate
and adaptive immunity are involved in the immuno-
reaction induced by lactoferrin or its derivatives
(Figure 2).49,53–56 As a result of the cyclic change in
Nutrition Reviews® Vol. 72(12):763–773768
lactoferrin concentration, the secretory components,
such as immunoglobulin (Ig) A and IgG, increase sharply
at proestrus in the uterus and decline in the other stages.71
In cancer, lactoferrin functions predominantly by activat-
ing a strong Th1 response and the release of anticancer
killer cells.53 The recruitment of lymphocytes, mainly
including CD4+ and CD8+, reaches up to a 20-fold
increase within treated animals after oral administration
of bovine lactoferrin.49 The tumor-inﬁltrating lympho-
cytes can greatly inhibit the proliferation of cancers.72
The expression of interferon-γ, tumor necrosis
factor-α (TNF-α), caspase-1, and interleukin (IL)-18, as
well as IgM+ and IgA+ B cells, is also signiﬁcantly
increased in the small intestine after bovine lactoferrin
treatment.54–56,73,74 Actually, a cascade eﬀect exists among
these proteins. Caspase-1 is known to cleave pro-IL-18 to
generate mature IL-18.54 IL-18 is an interferon-γ-
inducing cytokine.75 Further, IL-18 has an important role
in the expression of TNF-γ in T cells and natural killer
cells and as a stimulator of TNF-α and several other
cytokines. IL-18 can also enhance Th1 and natural killer
cell responses and generate CD8+ eﬀector T cells.76 Sys-
temic and intralesional administration of IL-18 signiﬁ-
cantly inhibited the growth of tumors.75 In addition,
lactoferrin can increase the eﬀector functions of natural
killer cells and macrophages at low concentrations and
enhance the production of nitric oxide that has been
reported to sensitize tumors to chemotherapy.60,77 More-
over, orally administered bovine lactoferrin was found to
systemically restrict VEGF165-mediated angiogenesis in
rats.40,78 The combined eﬀects of these factors may, there-
fore, lead to the eradication of tumors and blocking of
pathogens. In addition, lactoferrin can ﬂexibly bind and
release several kinds of metal-related cations, such as
Zn,2+ Fe,3+ Cu,2+ Mn3+, and Ga.3+ 4 Indeed, lactoferrin acts
as one of the main iron regulators in the human body and
is responsible for maintaining systemic iron homeosta-
sis.79 Iron balance is necessary for cell growth and enzyme
activity. If unbalanced, iron can become a potentially
toxic element, leading to the formation of free radicals.
These radicals induce a cellular redox imbalance by pro-
ducing oxidative stress, which may be related to onco-
genic stimulation.80 As such, lactoferrin may be an
eﬀective chelator to maintain the balance of iron in vivo.
Furthermore, iron chelators have been shown to possess
antiproliferative activity both in vitro and in vivo.81
ENHANCING THE ANTICANCER EFFECTS OF
LACTOFERRIN AND ITS DERIVATIVES
Currently, it is recognized and has been demonstrated
that lactoferrin and its derivatives possess anticancer
activities.16–18,48 Moreover, their use in combination with
other agents has proven highly successful.15,82–87 There-
fore, it is thought that lactoferrin and its derivatives
Figure 2 In vivo anticancer eﬀects of bovine lactoferrin.Oral administration of bovine lactoferrin eﬃciently activates B and
T cells and increases the eﬀect of natural killer cells and macrophages, while the expression of IFN-γ, TNF-α, caspase-1, and
IL-18 increases signiﬁcantly. A cascade eﬀect with these proteins further ampliﬁes the anticancer eﬀect, which eﬃciently
inhibits carcinogenesis, tumor proliferation, and tumor angiogenesis during tumor development.
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synergize with other known anticancer agents or delivery
systems in order to generate their cytotoxic eﬀects against
cancer.
The ability to speciﬁcally target a tumor is one of the
desired properties of an ideal antitumor drug. An appro-
priate delivery system can be very helpful in getting
lactoferrin and its derivatives to the tumor.Massodi et al.82
developed an elastin-like polypeptide carrier to deliver the
peptide derivative of bovine lactoferrin-L12.18 The ther-
mally responsive assemblage is soluble in aqueous solu-
tions at 37°C but aggregates near 41°C, which makes it an
ideal carrier for targeting solid tumors when treatment is
focused on hyperthermia, for example during radio-
therapy.On the other hand, liposomes are an eﬃcient drug
delivery system and can greatly enhance the therapeutic
potential of the encapsulated compounds. Liposome-
entrapped iron-free lactoferrin (apolactoferrin) demon-
strated a clearly enhanced inhibitory eﬀect on the growth
of B16–F10 cells.83 In addition, a brain-targeted chemo-
therapeutical delivery system, doxorubicin-loaded
lactoferrin-modiﬁed procationic liposome, eﬃciently
raised the uptake and cytotoxicity of lactoferrin against
glioma C6 cells.87 Furthermore, several studies success-
fully used adenovirus to target lactoferrin to cancers in
animal models.85,86 These recombinant adenoviruses
could signiﬁcantly suppress the growth of tumors by
releasing lactoferrin within solid tumors.
Combining lactoferrin or its variants with recog-
nized anticancer agents is another eﬀective way to
increase the anticancer activity of chemotherapeutic
agents. Tumors in mice fed hololactoferrin were com-
pletely eliminated with a single injection of known che-
motherapeutic agents.77 In vitro experiments in breast
cancer cells showed bovine lactoferricin to have greatly
augmented cytotoxic eﬀects when combined with
C6-ceramide and tamoxifen.15 Another interesting study
revealed that a combination of human neutrophil
peptide-1 and human lactoferrin could kill cancer cells
without aﬀecting normal cells. Neither human neutrophil
peptide-1 nor human lactoferrin could demonstrate this
eﬀect individually.84 The selective cytotoxicity against
cancers is the most important feature of any antitumor
drug. Therefore, these case studies suggest that the com-
bination of lactoferrin or its derivatives with other anti-
cancer agents could represent an eﬃcient way to boost
the cytotoxic eﬀects and, consequently, the performance
of these agents against cancers, with limited side eﬀects.
CLINICAL APPLICATIONS AND FUTURE TRENDS FOR
LACTOFERRIN IN CANCER THERAPY
Although there is still some uncertainty about the mecha-
nisms underlying the cytotoxicity of lactoferrin and its
derivatives against cancer, there is no doubt about its
potential anticancer activity. Since lactoferrin and its
derivatives are food-derived components, and thus non-
toxic, they constitute an interesting alternative to
chemoprevention and the currently used anticancer
drugs. In addition, its stability through the gastrointesti-
nal tract is beneﬁcial if oral administration is envisaged.
All of these features are believed to be essential for an
eﬃcient drug. To date, several clinical trials have been
initiated to evaluate the therapeutic eﬀects of lactoferrin
in cancer therapy, such as for non-small-cell lung cancer
(clinical trial registration no. NCT00706862) and renal
cell carcinoma (clinical trial registration no.
NCT00095186). Since the trial for non-small-cell lung
cancer was ongoing at the time of manuscript prepara-
tion, a comprehensive evaluation of the results was not
available. Lactoferrin has been found to be useful for
reducing some clinical complications associated with
chemotherapy, such as anemia,88 and immunoreaction
stimulated by lactoferrin is thought to be a key factor in
cancer therapy.
Most of the data on the anticancer eﬀects of lacto-
ferrin are based on in vitro studies, in which lactoferrin
and its derivatives have been shown to greatly inhibit
the proliferation of various cancer cells.11–17,19,47,50–52
This means that their cytotoxicity is probably due to the
direct contact between lactoferrin and cancer cells. Thus,
the direct and indirect actions of lactoferrin should be
fully explored so that a greater anticancer eﬀect can be
obtained in vivo (Figure 3). The direct action of
lactoferrin can be achieved by intratumoral or intrave-
nous injection. Unfortunately, though, lactoferrin can be
quickly cleared after intravenous administration.89 In
light of this, perhaps a tumor-targeting delivery system,
which will prevent the protein from degrading before it
reaches the tumor cells, would improve the anticancer
eﬀects in vivo. Currently, several carrier vectors, involv-
ing systemic targeting as well as intracellular targeting,
are available to deliver anticancer agents. Both the widely
used liposomes and the emergent nanoparticles have
proved to be eﬃcient carriers whose further use in clinical
practice is supported.90 They may be modiﬁed with spe-
ciﬁc ligands to target tumor cells or to just remain in
circulation longer, thus providing a slow release of
lactoferrin or its variants, thereby persistently activating
the immune system. This approach has the potential to
greatly reduce any possible adverse eﬀects and increase
the agent’s performance against cancer. In addition, the
combination of lactoferrin and its derivatives with estab-
lished anticancer agents has been shown to result in
increased killing of cancer cells in vitro82,83,87 and should
be further explored.With this approach, the ﬁrst clinical
use of lactoferrin is envisaged as an adjuvant therapeutic
agent in cancer patients. This will not only take advantage
of the immunotherapeutic eﬀects of lactoferrin, it will
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also provide anticancer eﬀects superior to those obtained
when chemotherapy agents are used alone.
CONCLUSION
Lactoferrin is amultifunctional protein that can be widely
found in most mammalian cells. Its expression is regu-
lated by several factors to maintain homeostasis. Silenc-
ing or downregulation of the lactoferrin gene in cells is
usually related to the occurrence of certain diseases, espe-
cially carcinomas. Restoration of lactoferrin gene expres-
sion can eﬀectively inhibit the proliferation of cancer
cells. The response elements of disease-related factors in
the lactoferrin promoter and its adjacent regions could
partly explain the vital role this protein plays in the pre-
vention of serious diseases. Cytotoxic assays also demon-
strated the inhibitory eﬀects of lactoferrin and its
derivatives against the proliferation of multiple cancers,
thus suggesting a potential role in cancer prevention.
However, the mechanisms involved in the cytotoxicity of
lactoferrin and its derivatives against cancer are derived
from in vitro experiments and are not always conclu-
sive.11,12,16,17,19 Fortunately, however, the conclusions
drawn from in vivo experiments about the mechanisms
involved are similar, i.e., tumors are eliminated due to the
lactoferrin-stimulated increase in tumor-killer cells.49,54–56
Although clinical trials involving the use of
lactoferrin in cancer therapy are ongoing, there are still
no reports about the use of lactoferrin in clinical practice.
The relatively low cytotoxicity of lactoferrin and its
derivatives as compared with known anticancer drugs,
along with the lack of data about the mechanisms of
action, is likely hampering the clinical use of lactoferrin in
cancer treatment. However, as previously mentioned,
lactoferrin and its derivatives could be an eﬀective anti-
cancer treatment modality if combined with other thera-
peutic agents or if encapsulated in carriers after
appropriate modiﬁcations. It is interesting to note that
some studies have already begun to use these approaches
to increase the cytotoxic eﬀects of lactoferrin and its
derivatives.15,82,83 As combination therapy becomes
increasingly popular, it is likely that lactoferrin will con-
tinue to be studied for its potential value as a primary or
adjuvant agent in the treatment of cancer.
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